A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Dulox

描述(申请人提供)：纤维肌痛(FMS)，定义为既存在慢性广泛性疼痛，又在检查中发现11/18痛点，影响2%的总人口。在FMS管理和研究中最受关注的两种治疗方法是认知行为疗法(CBT)和药物疗法。虽然药物治疗在改善FMS相关症状方面最有效，但CBT已被证明在改善FMS相关残疾方面更有用。鉴于单一疗法(药物或CBT单独治疗)似乎只能适度减轻疼痛，现在是时候考虑更仔细地研究包括药物和CBT在内的联合治疗，以优化治疗反应。更重要的是，人们对两种不同的治疗策略如何单独或联合作用以提高结果的机制知之甚少。因此，我们建议进行一项三臂随机注意力对照试验，其主要目的是测试CBT和度洛西汀联合治疗方法的可行性，并对其效果进行初步估计，以用于设计更大规模的试验。这项初步研究将招募48名FMS患者，将他们随机分成3组之一：(1)CBT-度洛西汀联合组，(2)CBT-安慰剂组，或(3)度洛西汀-教育组(注意)。从第1周到第9周，受试者将接受8次电话CBT或教育指导。此外，从第1周到第21周，受试者将接受度洛西汀或安慰剂治疗。基线(第1周)、第9周和第21周的结果评估将包括以下内容：自我报告疼痛严重程度和身体功能、与疼痛相关的信念以及应对和诱发疼痛的敏感度。这项研究计划将使我们能够探索基于心理的治疗的生物学机制，以及基于生物的治疗的心理机制。与公共卫生相关：鉴于单一疗法(药物或CBT单独)似乎只能产生适度的疼痛减轻，拟议的研究具有重要意义，因为CBT和度洛西汀的组合具有相当大的潜力，可以最大限度地发挥治疗效果。更重要的是，探索联合治疗背后的生物和心理机制可能为开发FMS患者的新治疗方法铺平道路。

DESCRIPTION (provided by applicant): Fibromyalgia (FMS), defined as the presence of both chronic widespread pain and the finding of 11/18 tender points on examination, affects 2% of the general population. The two treatment approaches that have received the most attention in FMS management and research are cognitive behavioral therapy (CBT) and drug therapy. Whereas drug therapy is most effective for improving the symptoms associated with FMS, CBT has been shown to be more useful for improving the FMS-related disability. Given the fact that mono-therapies (drug or CBT alone) appear to only produce modest reductions in pain, it is time to consider more careful study of combination treatment that includes drug and CBT to optimize treatment response. More importantly, little is known about the mechanisms of how two different treatment strategies would work alone or in combination to enhance outcomes. Therefore, we propose to conduct a 3-arm randomized attention-controlled trial whose primary aim is to test the feasibility of combined CBT and duloxetine treatment approach, and obtain preliminary estimates of its effect for use in designing a larger trial. This pilot study will enroll 48 FMS patients, randomizing them to one of the 3 groups: (1) combination CBT-duloxetine, (2) CBT-placebo, or (3) duloxetine-education (attention) group. From week 1 to 9, subjects will receive 8 sessions of telephone-delivered CBT or educational instructions. Additionally, from week 1 to 21, subjects will receive duloxetine or placebo. Outcome assessments at baseline (week 1), week 9 and week 21 will include the following: self-report pain severity and physical function, pain-related beliefs and coping and evoked pain sensitivity. This program of research would enable us to explore biological mechanisms of a psychological-based therapy, and the psychological mechanisms of a biological-based therapy. PUBLIC HEALTH RELEVANCE: Given the fact that mono-therapies (drug or CBT alone) appear to only produce modest reductions in pain, the proposed research is significant because the combination CBT and duloxetine has considerable potential to maximize treatment response. More importantly, exploring the biological and psychological mechanisms underlying combination treatment may pave the way for developing new treatments for FMS sufferers.